filmov
tv
Integrated Phenotypic Screening and Target Deconvolution for Accelerated Drug Discovery
Показать описание
Click here to register for free and to view the entire webinar:
Speakers:
Mark Slack, PhD, Vice President, In Vitro Pharmacology, Evotec
Stefan Müller, PhD, Head of Chemical Biology, Evotec
Using phenotypic screens as a strategy to identify potential drug candidates has gained renewed attention in recent years. The aim is to identify chemical matter that corrects disease-relevant cellular phenotypes with the potential to be truly disease-modifying. To this end, Evotec has established innovative and novel disease-relevant screening paradigms. This webinar will provide insight into Evotec’s approach to phenotypic screening for hit ID in the context of complex & novel biological systems.
Understanding the mechanism and binding partner(s) of any hit compounds identified from phenotypic screening has posed a challenge for many years. Evotec’s Cellular Target Profiling™ approach combines quantitative mass spectrometry based chemical proteomics to identify the target(s) of small molecule hit compounds. The technology uses cells to reveal a compound’s cellular binding partners including binding affinities thus allowing deciphering the network of intracellular targets and enabling lead optimization.
The webinar will focus on:
Use of novel disease-relevant cellular systems for hit ID including the use of stem cells
Characterization and prioritization of hits for target identification post HTS
Target deconvolution through mass spec-based Cellular Target Profiling
Speakers:
Mark Slack, PhD, Vice President, In Vitro Pharmacology, Evotec
Stefan Müller, PhD, Head of Chemical Biology, Evotec
Using phenotypic screens as a strategy to identify potential drug candidates has gained renewed attention in recent years. The aim is to identify chemical matter that corrects disease-relevant cellular phenotypes with the potential to be truly disease-modifying. To this end, Evotec has established innovative and novel disease-relevant screening paradigms. This webinar will provide insight into Evotec’s approach to phenotypic screening for hit ID in the context of complex & novel biological systems.
Understanding the mechanism and binding partner(s) of any hit compounds identified from phenotypic screening has posed a challenge for many years. Evotec’s Cellular Target Profiling™ approach combines quantitative mass spectrometry based chemical proteomics to identify the target(s) of small molecule hit compounds. The technology uses cells to reveal a compound’s cellular binding partners including binding affinities thus allowing deciphering the network of intracellular targets and enabling lead optimization.
The webinar will focus on:
Use of novel disease-relevant cellular systems for hit ID including the use of stem cells
Characterization and prioritization of hits for target identification post HTS
Target deconvolution through mass spec-based Cellular Target Profiling
Integrated Phenotypic Screening and Target Deconvolution for Accelerated Drug Discovery
Integrating Target-based and Phenotypic Screening Strategies with Human Cardiomyocytes
Integrated Platform for Hit Identification ～Phenotypic Drug Discovery～
Phenotypic Screening | Phenotypic Drug Discovery |
Phenotypic Screening - Advancing The Science From Discovery To Regulatory Science
Phenotypic Drug Discovery Platform
Phenotypic screening hit target deconvolution using CRISPR/Cas9 screening technology | AAPS 2021
Target-Based Drug Discovery in Cancer Research
High-Content Phenotypic Screening - Answering Questions You Haven't Even Asked Yet
HTS and Cell-Based Phenotypic Screening to Identify Potential Cardiac and Cardiovascular Liabilities
KS Insights: Phenotypic Drug Discovery
The Drug Discovery Funnel: System-Based vs. Target-Based
Basics of Phenotypic Screening
Integrated HTS platform for innovative drug discovery
Phenotypic and Target Based Drug Discovery: Approaches for the Discovery of Innovative Therapeutics
Combining Target Based and Phenotypic Discovery Assays for Drug Repurposing
Combining Phenotypic and Biochemical Screening to Identify Drug Targets
Edgar Jacoby - The Interplay of Kinase Broad Profiling and Phenotypic Screening
Phenotypic Drug Discovery - Webinar (Part One)
Target to Phenotype: Tools to Accelerate Your Immuno-Oncology Drug Pipeline
Integrated Plattform for Hit Identification ～Hit characterization in Post HTS～
Identification of chemical leads to drug targets by high throughput screening...'
Combining Target Based and Phenotypic Discovery Assays for Drug Repurposing
